NGM 282

Drug Profile

NGM 282

Alternative Names: NGM-282

Latest Information Update: 22 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Cholesterol 7 alpha hydroxylase inhibitors; Fibroblast growth factor receptor modulators; Type 1 fibroblast growth factor receptor modulators; Type 4 fibroblast growth factor receptor modulators; Type-2 fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Type 2 diabetes mellitus
  • Phase I/II Constipation

Most Recent Events

  • 06 May 2017 Safety and efficacy data from a phase Ib/II trial in Constipation presented at the Digestive Disease Week (DDW-2017)
  • 22 Apr 2017 Safety and efficacy data from a phase II clinical trial in Non-alcoholic steatohepatitis released by NGM Biopharmaceuticals
  • 19 Apr 2017 Preclinical pharmacodynamics data from a in Non- alcoholic steatohepatitis released by NGM Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top